Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin

Tuberculosis (TB) is the cause of more than one million deaths worldwide, and despite being a curable disease, some factors can make therapy difficult, emphasizing the need for the development of new drugs that may potentiate the action of the classic anti-TB antimicrobials. Naphthoimidazoles show a broad spectrum of biological activities, including antimycobacterial activity. The aim of this study was to evaluate the anti-Mycobacterium tuberculosis activity of nine naphthoimidazoles, alone and combined with isoniazid (INH) and rifampicin (RIF).

Source: Tuberculosis - July 2, 2018 Category: Respiratory Medicine Authors: L élia Pacheco Corrêa Barros, Karina Pena Del Rio, Tatiane dos Santos Conceição Carvalho, Maria do Carmo Freire Ribeiro Pinto, Kelly Cristina Gallan de Moura, Priscila Cristina Bartolomeu Halicki, Daniela Fernandes Ramos, Pedro Eduardo Almeida da Silv Tags: Drug Discovery and Resistance Source Type: research